Co-morbidity and familial aggregation of alcoholism and anxiety disorders.

Department of Epidemiology, Yale University School of Medicine, New Haven, CT 06510, USA.
Psychological Medicine (Impact Factor: 5.43). 08/1998; 28(4):773-88.
Source: PubMed

ABSTRACT This study examined the patterns of familial aggregation and co-morbidity of alcoholism and anxiety disorders in the relatives of 165 probands selected for alcoholism and/or anxiety disorders compared to those of 61 unaffected controls.
Probands were either selected from treatment settings or at random from the community. DSM-III-R diagnoses were obtained for all probands and their 1053 first-degree relatives, based on direct interview or family history information.
The findings indicate that: (1) alcoholism was associated with anxiety disorders in the relatives, particularly among females; (2) both alcoholism and anxiety disorders were highly familial; (3) the familial aggregation of alcoholism was attributable to alcohol dependence rather than to alcohol abuse, particularly among male relatives; and (4) the the pattern of co-aggregation of alcohol dependence and anxiety disorders in families differed according to the subtype of anxiety disorder; there was evidence of a partly shared diathesis underlying panic and alcoholism, whereas social phobia and alcoholism tended to aggregate independently.
The finding that the onset of social phobia tended to precede that of alcoholism, when taken together with the independence of familial aggregation of social phobia and alcoholism support a self-medication hypothesis as the explanation for the co-occurrence of social phobia and alcoholism. In contrast, the lack of a systematic pattern in the order of onset of panic and alcoholism among subjects with both disorders as well as evidence for shared underlying familial risk factors suggests that co-morbidity between panic disorder and alcoholism is not a consequence of self-medication of panic symptoms. The results of this study emphasize the importance of examining co-morbid disorders and subtypes thereof in identifying sources of heterogeneity in the pathogenesis of alcoholism.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Alcoholism is a chronic relapsing brain disorder. Several clinical and preclinical studies indicate that alcohol use disorders (AUD) and anxiety disorders are highly correlated and have a shared etiology, promoting each other’s development and also feeding back into each other’s maintenance. The molecular and epigenetic mechanisms in specific brain circuitry such as the central nucleus of amygdala (CeA) may be involved in the comorbidity of anxiety and alcoholism. Innate or ethanol-induced changes in signaling cascade pathways leading to adaptations at the level of cAMP responsive element–binding (CREB) protein gene-transcription factor function and associated chromatin remodeling due to histone modifications and DNA methylation in the CeA have become one of the emerging mechanisms underlying AUD and anxiety. Studies conducted in the field suggest that histone deacetylases and DNA methyltransferase inhibitors may be potential therapeutic agents to treat or prevent alcoholism with or without comorbid anxiety disorders.
    Neurobiology of Alcohol Dependence, 1st edited by A Noronha, C. Cui, R.A. Harris, J.C. Crabbe, 01/2014: chapter 22: pages 451-466; Elsevier Inc., ISBN: 978-0-12-405941-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A substantial amount of evidence suggests that dysfunction of the dopamine transporter may be involved in the pathophysiology of amphetamine dependence (AD). The aim of this study was to examine whether the dopamine transporter gene (DAT1, SLC6A3) is associated with development of AD and whether this gene influences personality traits in patients with AD. Eighteen polymorphisms of the DAT1 gene were analyzed in a case-control study that included 909 Han Chinese men (568 patients with AD and 341 control subjects). The patients fulfilled the DSM-IV-TR criteria for AD. The Tridimensional Personality Questionnaire (TPQ) was used to assess personality traits and to examine the association between these traits and DAT1 gene variants. A weak association was found between the rs27072 polymorphism and development of AD, but these borderline associations were unconfirmed by logistic regression and haplotype analysis. Although harm avoidance and novelty seeking scores were significantly higher in patients than in controls, DAT1 polymorphisms did not influence these scores. This study suggests that high harm avoidance and novelty seeking personality traits may be a risk factor for the development of AD. However, the DAT1 gene may not contribute to AD susceptibility and specific personality traits observed in AD among Han Chinese men. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
    Drug and Alcohol Dependence 02/2015; 149. DOI:10.1016/j.drugalcdep.2015.01.030 · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dopamine transporter and its genetic factors have been suggested to play a critical role in the development of bipolar disorder (BPD). However, the importance of the dopamine transporter gene (DAT1) in the pathogenesis of BPD remains unclear. The aims of this study were to assess 18 polymorphisms of the DAT1 gene to determine whether this gene is associated with BPD and whether it influences personality traits of patients with BPD. DAT1 polymorphisms were analyzed in 492 BPD (374 BPDI and 118 BPDII) patients and 436 controls. All participants were screened using the same assessment tool, and all met the criteria for BPD. The Tridimensional Personality Questionnaire was used to assess personality traits in both patients and controls. Several polymorphisms had a weak association with BPD, including rs2550948, rs2652511, and rs2975226 in allele distribution analysis (P < 0.05). Furthermore, the promoter G-A-C-G haplotype (rs6350-rs2975226-rs2652511-rs6413429) was over-represented in the BPD patients compared to the controls (P = 0.007). In personality assessment, the BPDII patients had the highest harm avoidance score, followed by the BPDI patients and controls (P = 3.7 × 10(-32)). In addition, a significant association between rs40184 and harm avoidance was found in the patients with BPD. The DAT1 promoter may be associated with vulnerabilities in BPD. The BPD patients had a higher rate of harm avoidance personality traits than the controls, and DAT1 variants may influence personality traits in patients with BPD.
    European Archives of Psychiatry and Clinical Neuroscience 12/2014; 265(4). DOI:10.1007/s00406-014-0570-0 · 3.36 Impact Factor

Preview (2 Sources)

Available from